Jaguar Health shares slump following Phase III Mytesi failure
snippet
Jaguar Health said an initial analysis of anti-diarrhoeal drug Mytesi (crofelemer) in cancer patients showed the Phase III trial did not meet its primary endpoint.
Shares in the Nasdaq-listed company opened 66% lower compared to a pre-announcement market close. Jaguar has a market cap of $12m.
Source
Clinical Trials Arena